Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BOSTON, March 02, 2017 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that it will host a conference call on Thursday, March 9, 2017 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2016.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 77476849. The call will also be webcast live on the Company's website at http://ir.zafgen.com/events.cfm. A replay of this conference call will be available beginning at 7:30 p.m. ET on March 9, 2017 through March 16, 2017 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide Conference ID number 77476849.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of metabolic diseases through the MetAP2 pathway. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. Zafgen's lead product candidate is ZGN-1061, which is a novel, first-in-class, twice-weekly subcutaneous injection. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.
Investor Relations Contact: Argot Partners Investor Relations Laura Perry or Glenn Garmont 212-600-1902 [email protected] [email protected]
